Key Segments:
By Product Type
-
Prefilled Syringes & Autoinjectors
-
Inhalers
-
Transdermal Patches
-
Drug-Eluting Stents
-
Infusion Pumps
-
Drug-Eluting Balloons & Catheters
-
Other Product Types
By Route of Administration
-
Parenteral
-
Transdermal
-
Implantable
-
Oral
By Application
-
Diabetes
-
Cardiovascular Disorders
-
Respiratory Diseases
-
Oncology
-
Pain Management
-
Ophthalmology
-
Other Applications
By End User
-
Hospitals & Clinics
-
Ambulatory Surgical Centers
-
Home Care Settings
-
Other End Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Becton, Dickinson and Company, SHL Medical AG, Ypsomed Holding AG, West Pharmaceutical Services, Stevanato Group, Gerresheimer AG, Terumo Corporation, Enable Injections, Aptar Pharma, Nipro Corporation, Phillips-Medisize, Teva Pharmaceutical Industries, Medtronic, Abbott Laboratories, Boston Scientific, Johnson & Johnson MedTech, GSK, AstraZeneca, Catalent and Vetter Pharma-Fertigung, among others.
Opportunities include connected autoinjectors and patch pumps for home-care adherence monitoring, expanding self-injectable biologic access across emerging markets, and non-invasive transdermal and microneedle platforms for new drug classes.
Growth is primarily driven by the rapid shift of biologic and GLP-1 therapies toward self-administration, which is expanding demand for autoinjectors, prefilled syringes and wearable on-body injectors.
The Prefilled Syringes & Autoinjectors segment dominated the market in 2025 with approximately 31.65% share.
North America dominated the market in 2025 with approximately 41.85% share.
